Cargando…

Are large simple trials for dementia prevention possible?

New trials of dementia prevention are needed to test novel strategies and agents. Large, simple, cardiovascular trials have successfully discovered treatments with moderate but worthwhile effects to prevent heart attack and stroke. The design of these trials may hold lessons for the dementia prevent...

Descripción completa

Detalles Bibliográficos
Autores principales: Whiteley, William N, Anand, Sonia, Bangdiwala, Shrikant I, Bosch, Jackie, Canavan, Michelle, Chertkow, Howard, Gerstein, Hertzel C, Gorelick, Philip, O’Donnell, Martin, Paré, Guillaume, Pigeyre, Marie, Seshadri, Sudha, Sharma, Mike, Smith, Eric E, Williamson, Jeff, Cukierman-Yaffe, Tali, Hart, Robert G, Yusuf, Salim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047819/
https://www.ncbi.nlm.nih.gov/pubmed/31830268
http://dx.doi.org/10.1093/ageing/afz152
_version_ 1783502187168530432
author Whiteley, William N
Anand, Sonia
Bangdiwala, Shrikant I
Bosch, Jackie
Canavan, Michelle
Chertkow, Howard
Gerstein, Hertzel C
Gorelick, Philip
O’Donnell, Martin
Paré, Guillaume
Pigeyre, Marie
Seshadri, Sudha
Sharma, Mike
Smith, Eric E
Williamson, Jeff
Cukierman-Yaffe, Tali
Hart, Robert G
Yusuf, Salim
author_facet Whiteley, William N
Anand, Sonia
Bangdiwala, Shrikant I
Bosch, Jackie
Canavan, Michelle
Chertkow, Howard
Gerstein, Hertzel C
Gorelick, Philip
O’Donnell, Martin
Paré, Guillaume
Pigeyre, Marie
Seshadri, Sudha
Sharma, Mike
Smith, Eric E
Williamson, Jeff
Cukierman-Yaffe, Tali
Hart, Robert G
Yusuf, Salim
author_sort Whiteley, William N
collection PubMed
description New trials of dementia prevention are needed to test novel strategies and agents. Large, simple, cardiovascular trials have successfully discovered treatments with moderate but worthwhile effects to prevent heart attack and stroke. The design of these trials may hold lessons for the dementia prevention. Here we outline suitable populations, interventions and outcomes for large simple trials in dementia prevention. We consider what features are needed to maximise efficiency. Populations could be selected by age, clinical or genetic risk factors or clinical presentation. Patients and their families prioritise functional and clinical outcomes over cognitive scores and levels of biomarkers. Loss of particular functions or dementia diagnoses therefore are most meaningful to participants and potential patients and can be measured in large trials. The size of the population and duration of follow-up needed for dementia prevention trials will be a major challenge and will need collaboration between many clinical investigators, funders and patient organisations.
format Online
Article
Text
id pubmed-7047819
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-70478192020-03-03 Are large simple trials for dementia prevention possible? Whiteley, William N Anand, Sonia Bangdiwala, Shrikant I Bosch, Jackie Canavan, Michelle Chertkow, Howard Gerstein, Hertzel C Gorelick, Philip O’Donnell, Martin Paré, Guillaume Pigeyre, Marie Seshadri, Sudha Sharma, Mike Smith, Eric E Williamson, Jeff Cukierman-Yaffe, Tali Hart, Robert G Yusuf, Salim Age Ageing New Horizons New trials of dementia prevention are needed to test novel strategies and agents. Large, simple, cardiovascular trials have successfully discovered treatments with moderate but worthwhile effects to prevent heart attack and stroke. The design of these trials may hold lessons for the dementia prevention. Here we outline suitable populations, interventions and outcomes for large simple trials in dementia prevention. We consider what features are needed to maximise efficiency. Populations could be selected by age, clinical or genetic risk factors or clinical presentation. Patients and their families prioritise functional and clinical outcomes over cognitive scores and levels of biomarkers. Loss of particular functions or dementia diagnoses therefore are most meaningful to participants and potential patients and can be measured in large trials. The size of the population and duration of follow-up needed for dementia prevention trials will be a major challenge and will need collaboration between many clinical investigators, funders and patient organisations. Oxford University Press 2020-02 2019-12-12 /pmc/articles/PMC7047819/ /pubmed/31830268 http://dx.doi.org/10.1093/ageing/afz152 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the British Geriatrics Society. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle New Horizons
Whiteley, William N
Anand, Sonia
Bangdiwala, Shrikant I
Bosch, Jackie
Canavan, Michelle
Chertkow, Howard
Gerstein, Hertzel C
Gorelick, Philip
O’Donnell, Martin
Paré, Guillaume
Pigeyre, Marie
Seshadri, Sudha
Sharma, Mike
Smith, Eric E
Williamson, Jeff
Cukierman-Yaffe, Tali
Hart, Robert G
Yusuf, Salim
Are large simple trials for dementia prevention possible?
title Are large simple trials for dementia prevention possible?
title_full Are large simple trials for dementia prevention possible?
title_fullStr Are large simple trials for dementia prevention possible?
title_full_unstemmed Are large simple trials for dementia prevention possible?
title_short Are large simple trials for dementia prevention possible?
title_sort are large simple trials for dementia prevention possible?
topic New Horizons
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047819/
https://www.ncbi.nlm.nih.gov/pubmed/31830268
http://dx.doi.org/10.1093/ageing/afz152
work_keys_str_mv AT whiteleywilliamn arelargesimpletrialsfordementiapreventionpossible
AT anandsonia arelargesimpletrialsfordementiapreventionpossible
AT bangdiwalashrikanti arelargesimpletrialsfordementiapreventionpossible
AT boschjackie arelargesimpletrialsfordementiapreventionpossible
AT canavanmichelle arelargesimpletrialsfordementiapreventionpossible
AT chertkowhoward arelargesimpletrialsfordementiapreventionpossible
AT gersteinhertzelc arelargesimpletrialsfordementiapreventionpossible
AT gorelickphilip arelargesimpletrialsfordementiapreventionpossible
AT odonnellmartin arelargesimpletrialsfordementiapreventionpossible
AT pareguillaume arelargesimpletrialsfordementiapreventionpossible
AT pigeyremarie arelargesimpletrialsfordementiapreventionpossible
AT seshadrisudha arelargesimpletrialsfordementiapreventionpossible
AT sharmamike arelargesimpletrialsfordementiapreventionpossible
AT smitherice arelargesimpletrialsfordementiapreventionpossible
AT williamsonjeff arelargesimpletrialsfordementiapreventionpossible
AT cukiermanyaffetali arelargesimpletrialsfordementiapreventionpossible
AT hartrobertg arelargesimpletrialsfordementiapreventionpossible
AT yusufsalim arelargesimpletrialsfordementiapreventionpossible